Mario Thevis

1 month ago | analyticalsciencejournals.onlinelibrary.wiley.com | Christian Reichel |Thomas Filip |Günter Gmeiner |Mario Thevis

1 Introduction ACE-031 (Ramatercept) is a soluble homodimeric fusion protein (ActRIIB-IgG1Fc, 343 amino acids) with three N-glycosylation sites [1], which binds (i.e. “traps” and thus blocks) activin receptor type II B (ActRIIB) ligands including myostatin [2]. Myostatin-inhibition leads to an increase in muscle mass and loss of fat. ACE-031 was primarily developed to treat myopathies in humans (e.g., Duchenne muscular dystrophy) [3].

2 months ago | dx.doi.org | Mario Thevis |Katja Walpurgis |Andreas Thomas

ReviewMarch 10, 2025*Mario ThevisCenter for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, GermanyEuropean Monitoring Center for Emerging Doping Agents, 50933 Cologne, Germany*Email: [email protected] Tel.: +49 2214982 7070 Fax: +49 2214982 7071.

Oct 3, 2024 | analyticalsciencejournals.onlinelibrary.wiley.com | Mario Thevis

Between February 26th and February 29th of the Olympic Year 2024, the 42nd edition of the Manfred Donike Workshop on Doping Analysis was conducted in Cologne, Germany.

Nov 7, 2023 | analyticalsciencejournals.onlinelibrary.wiley.com | Mario Thevis

After 2 years of virtual Manfred Donike Workshops,1 the 41st annual edition of this scientific event was conducted in-person again from February 26 until March 2, 2023. With 140 anti-doping scientists from 29 nations and all continents attending, a fantastic program was composed, and presentations of outstanding breadth and quality were contributed.